Searched for
INDIA BIOPHARMACEUTICALS
NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...
Why the world is betting on China again, and what India must do about itChina's business environment prioritizes market share with strong government backing. The nation has shifted to high-quality, high-speed pr...
Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
“Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
What to know about the Bundibugyo virus, a species of Ebola causing an outbreak in CongoA rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...
Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
Sun Pharma looks to outshine rival bids with $13 billion Organon offerSun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...
Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
AstraZeneca India plans to sell 64-acre Bengaluru site for Rs 3,400 croreThe land parcel, expected to fetch about ₹3,400 crore for AstraZeneca Pharma India, has drawn interest from developers including the Sattva...
Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitionsIndia's biopharmaceutical sector receives a significant boost with the Union Budget's ₹10,000 crore Biopharma SHAKTI programme. This initia...
- National Biopharma Mission launched
New Delhi, June 30 (IANS) The National Biopharma Mission aimed at accelerating biopharmaceutical development in the country was launched by...
India launches flagship program to boost biopharma productionThe ministry, which has received a loan of $125 million (over Rs 800 crore) from the World Bank for its “Innovate in India” (i3) program, h...
Time for India to be innovator nation in bio-pharmaceuticals: Expert"India has a strong potential to become a hub for bio-pharma innovation and play a leading role in collaborative research for the same."
Incoming Narendra Modi government represents opportunity to US business: PhRMAIncoming Modi-led govt represents an 'excellent opportunity' for American industries to strengthen & rekindle their relationships with Indi...
- Mauritius-based FIIs to pick up 47% in Intas' biotech arm
A clutch of investors are set to pick up 47% stake in the Intas Biopharmaceuticals, the biotech arm of Ahmedabad-based pharma major Intas P...